A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
This study is testing a new oral medication called nemtabrutinib to see if it safely and effectively stops the growth of various blood and lymph node cancers. The goal is to find new treatment options for patients whose cancers have not responded to standard therapies.
This study is open to adults who are currently managing specific types of blood or lymph cancers, such as CLL, SLL, or lymphoma. Participants must be well enough to care for their daily needs and be able to swallow pills.
Participants will take the study medication orally and have regular check-ups to monitor their health and how the cancer responds to the treatment. The medical team will closely watch for any side effects and track your progress throughout the study.
The study is currently recruiting patients at medical centers in Springdale, Arkansas, and La Jolla and Torrance, California. Please consult with your doctor to see if these locations are accessible for your ongoing care.
- 1The study uses an oral pill rather than an intravenous infusion.
- 2Participation requires being able to swallow pills reliably.
- 3Specific health requirements regarding Hepatitis B and C infections apply to ensure patient safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.